Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017
Abstract According to data presented at the 2017 American Society of Oncology (ASCO) Annual Meeting, with more than 4 years of follow-up, ibrutinib continues to provide clinical utility in chronic lymphocytic leukemia (CLL). However, treatment of CLL patients with high-risk cytogenetics features rem...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2017-08-01
|
| Sarja: | BMC Medicine |
| Aiheet: | |
| Linkit: | http://link.springer.com/article/10.1186/s12916-017-0920-7 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|